Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Phibro Animal Health (PAHC) Revenue (2016 - 2026)

Phibro Animal Health has reported Revenue over the past 14 years, most recently at $373.9 million for Q4 2025.

  • For Q4 2025, Revenue rose 20.9% year-over-year to $373.9 million; the TTM value through Dec 2025 reached $1.5 billion, up 32.39%, while the annual FY2025 figure was $1.3 billion, 27.37% up from the prior year.
  • Revenue for Q4 2025 was $373.9 million at Phibro Animal Health, up from $363.9 million in the prior quarter.
  • Over five years, Revenue peaked at $378.7 million in Q2 2025 and troughed at $211.7 million in Q1 2021.
  • A 5-year average of $270.2 million and a median of $252.5 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: decreased 0.5% in 2023 and later surged 39.73% in 2025.
  • Year by year, Revenue stood at $232.7 million in 2021, then rose by 5.13% to $244.6 million in 2022, then increased by 2.17% to $249.9 million in 2023, then grew by 23.73% to $309.3 million in 2024, then grew by 20.9% to $373.9 million in 2025.
  • Business Quant data shows Revenue for PAHC at $373.9 million in Q4 2025, $363.9 million in Q3 2025, and $378.7 million in Q2 2025.